MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
MDXH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
MDxHealth S.A.NASDAQ: MDXH
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $2M fell 22.3% year over year. Over 3 fiscal years it compounded at +11.1% a year.
Context
- Research & development amounted to 9.6% of revenue in FY2025, down 2.1 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 10.35M USD
- Year-over-year change
- -1.9%
- 4-year CAGR
- +16.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.35M | -1.9% |
| FY2024 | 2024-12-31 | 10.55M | +65.5% |
| FY2023 | 2023-12-31 | 6.38M | -15.6% |
| FY2022 | 2022-12-31 | 7.56M | +35.2% |
| FY2021 | 2021-12-31 | 5.59M | — |
Research & Development vs competitors
How MDXH compares with its peers on the latest reported figures
- MDXH's FY2025 research & development of $10.35M is the 7th highest of the 11 companies compared; the peer median is $35.69M.
- Its year-over-year change of -1.9% is the 9th highest of 11, against a peer median of +32.3%.
- Research & development amounts to 9.6% of revenue for MDXH, versus a peer median of 20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M | +48.2% | +21.1% | — |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
| LTM Mar 2026 | $33.21M | -3.4% | +10.2% | 22.9% | |
| FY2025 | $10.35M | -1.9% | +11.1% | 9.6% | |
| LTM Mar 2026 | $9.9M | +98.0% | — | 18.4% | |
| LTM Mar 2026 | $9.43M | -4.4% | -3.9% | 30.2% | |
| LTM Mar 2026 | $6.52M | +16.5% | -14.1% | 9.5% | |
| LTM Mar 2026 | $1.81M | +151.4% | +33.6% | 4.1% | |
| Peer median (excluding MDXH) | $35.69M | +32.3% | +5.1% | 20.6% | |
Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 22.24M | 37.05M | 70.19M | 90.05M | 107.88M |
| Cost of Revenue | 11.68M | 17.84M | 26.26M | 34.91M | 43.43M |
| Gross Profit | 10.56M | 19.22M | 43.93M | 55.14M | 64.44M |
| Gross Margin | 47.5% | 51.9% | 62.6% | 61.2% | 59.7% |
| Research & Development | 5.59M | 7.56M | 6.38M | 10.55M | 10.35M |
| Selling, General & Admin | 30.22M | 50.12M | 59.93M | 61.4M | 66.75M |
| Operating Expenses | 37.41M | 57.12M | 71.26M | 79.86M | 79.84M |
| Depreciation & Amortization | 3.04M | 4.91M | 6.86M | 8.04M | 9.21M |
| EBITDA | (24.09M) | (36.39M) | (30.47M) | (22.02M) | (14.01M) |
| EBITDA Margin | -108.3% | -98.2% | -43.4% | -24.5% | -13.0% |
| Operating Income | (26.84M) | (37.9M) | (27.33M) | (24.72M) | (15.4M) |
| Operating Margin | -120.7% | -102.3% | -38.9% | -27.5% | -14.3% |
| Interest Income | 11K | 125K | 1.09M | 1.08M | 1.5M |
| Interest Expense | 1.88M | 2.74M | 5.77M | 7.63M | 12.16M |
| Other Income / Expenses | (2.16M) | (6.14M) | (15.77M) | (12.97M) | (19.98M) |
| Income Before Tax | (29M) | (44.04M) | (43.1M) | (37.69M) | (35.38M) |
| Pre-Tax Margin | -130.4% | -118.9% | -61.4% | -41.9% | -32.8% |
| Income Tax Expense | 0 | 0 | 1K | 382K | (1.86M) |
| Net Income | (29M) | (44.04M) | (43.1M) | (38.07M) | (33.52M) |
| Net Margin | -130.4% | -118.9% | -61.4% | -42.3% | -31.1% |
| EPS (Basic) | (2.38) | (2.78) | (1.66) | (0.78) | (0.67) |
| EPS (Diluted) | (2.38) | (2.78) | (1.66) | (1.16) | (0.67) |
| Weighted Avg Shares | 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
| Weighted Avg Shares (Diluted) | 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.